PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

AnaSpec Key Supplier for Significant Study on pGlu Modified Beta-Amyloid Peptides - In the October 17, 2006 issue of Biochemistry, researchers performed a study that characterized the oligomerization and seeding capacity of pGlu-amyloid peptides
AnaSpec Key Supplier for Significant Study on pGlu Modified Beta-Amyloid Peptides

 

NewswireToday - /newswire/ - San Jose, CA, United States, 2007/01/22 - In the October 17, 2006 issue of Biochemistry, researchers performed a study that characterized the oligomerization and seeding capacity of pGlu-amyloid peptides.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Their results identified pGlu-modified beta-amyloid peptides as displaying “up to 250-fold accelerated initial formation of aggregates compared to unmodified Abeta”1, adding further support to the idea that pGlu-amyloid peptides possess “biophysical characteristics that might be in particular crucial for the initiation of [Alzheimer’s disease] (1).” AnaSpec was one of the primary sources for the peptides used in this study.

For more information, visit our website.

AnaSpec, Inc., located in San Jose, CA, is a leading provider of integrated proteomics solutions to pharmaceutical, biotech, and academic research institutions throughout the world. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents, and combinatorial chemistry.AnaSpec carries a broad product line of biochemicals and reagents for basic research, high-throughput screening and drug discovery. In conjunction, AnaSpec provides premier custom services including peptide synthesis, antibody production, and assay development. AnaSpec holds a California Drug Manufacturing License (License #41747) and a FDA Registration for GMP Drug Manufacturing (Registration #2951078).

Quality

As a company founded by researchers, we recognize the inextricable connection between the quality of one's tools and the success of one's research. Since our inception, AnaSpec has had a longstanding reputation for the unsurpassed quality of our products. AnaSpec's full commitment to quality is exemplified by our ISO 9001:2000 certification. All products are manufactured according to strict ISO and GMP/GLP guidelines and are accompanied with certificates of analysis. AnaSpec's peptides are produced in our own manufacturing facilities located in San Jose, CA.

Innovation

The scientific team at AnaSpec is staffed by experts in the fields of peptide technology, fluorescence technology, antibodies, and combinatorial chemistry. Our expertise in these complementary fields translates into both premium quality products and cutting-edge innovation.

Highlights:

Largest selection of peptides for Alzheimer research (200+ Amyloid Peptides) and phosphorylation studies (400+ Kinase and Phosphatase Substrates/Inhibitors)

Large number of phosphospecific antibodies, including phosphoserine antibodies exhibiting unrivalled selectivities

Leading fluorescence technologies generating new versatile fluorescent reagents such as HiLyte Fluor™ dyes and QXL™ quenchers useful for FRET and other fluorometric applications

Novel assay kits such as EnzoLyte™ AnaRed™ and EnzoLyte™ Rh110 Caspase 3 Assay Kits developed with greater selectivity and sensitivity for detection applications

Thousands of new building blocks and amino acid derivatives produced for medicinal and combinatorial chemistry
Ethical Service

Complementing our full commitment to product quality, AnaSpec provides unparalleled customer support. Our professional customer support staff is always ready to answer your order and technical inquiries with personalized, attentive care. Online ordering and custom project reports are available at our website for efficient purchasing and planning. Whatever your need is, you can always depend on us to assist you in a prompt and professional manner.

Integrated Proteomics Solutions

More than simply providing products or services, AnaSpec is singularly focused on providing solutions for the most demanding research challenges. The synergy of AnaSpec's technologies combined with a premium placed on the values of quality, innovation, and service, make AnaSpec uniquely qualified as the leading provider of Integrated Proteomics Solutions™.

References:
1. Schilling, S. et al Biochemistry 45, 12393 (2006)

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: AnaSpec, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


AnaSpec Key Supplier for Significant Study on pGlu Modified Beta-Amyloid Peptides

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Debra Thai 
408-452-5055 marketing[.]anaspec.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From AnaSpec, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  BizJobs.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)